Tag
Medicare Advantage beneficiaries receive fewer higher-cost anti-VEGF injections compared to Fee-for-Service patients, highlighting potential access disparities to newer ophthalmic therapies.
A 12-month follow-up of the REAGIR trial found no significant benefit of adjunctive rose bengal photodynamic therapy with green light over sham treatment in improving visual acuity, scar size, or complication rates in infectious keratitis.
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.
A rare, severe neurologic complication has been linked to general anesthesia in patients of maternal Venezuelan descent. Ophthalmologists should screen for ancestry and family history, involve anesthesiology early, and consider genetic eval
This review synthesizes evidence on improving geographic atrophy trial efficiency through innovative run-in phases, single-arm designs, and superior functional biomarkers like microperimetry to reduce required sample sizes.
A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.
A global task force has established new standardized imaging measures to define disease activity in non-infectious posterior uveitis, bridging a critical gap in clinical diagnosis and trial monitoring.
A new IOL power calculation formula, LISA MRS, demonstrates superior accuracy for cataract patients with prior myopic refractive surgery, significantly outperforming existing formulas in eyes with axial lengths of 28 mm or greater by utiliz
This review analyzes ophthalmic drug shortages from 2001 to 2024, revealing that eye medications face longer shortage durations than other drug classes, significantly influenced by patent status and manufacturing transparency.
A longitudinal study of 603 patients demonstrates that chronic intravitreal anti-VEGF therapy significantly accelerates cataract development, particularly posterior subcapsular opacities, resulting in an eightfold increased risk for catarac
This randomized pilot study demonstrates that high-frequency TENS significantly improves specific neuropathic ocular pain symptoms over three months, offering a non-invasive, non-pharmacological alternative for patients with refractory ocul
Recent data from the NIH All of Us Research Program indicates that Fuchs’ Endothelial Corneal Dystrophy (FECD) is associated with a significantly higher prevalence of cardiometabolic comorbidities, suggesting a systemic component to t
The SEE randomized clinical trial demonstrates that a 6-month personalized coaching program using motivational interviewing significantly improves glaucoma medication adherence and reduces patient distress compared to standard education.
A crossover study involving 30 ophthalmologists and trainees reveals that while Claude-3.5-Sonnet collaboration improves diagnostic accuracy in complex cases, it also increases confidence in incorrect decisions and fails to reach the perfor
A post hoc analysis of the TENAYA and LUCERNE trials demonstrates that early resolution of retinal fluid by week 12 with faricimab is a significant predictor of achieving extended every-16-week dosing intervals in patients with neovascular
This Phase 2/3 trial of QPI-1007 for NAION found that while the primary endpoint was not met for the general population, the siRNA therapy significantly preserved vision in patients with more severe baseline visual impairment.
The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal
Researchers have developed and validated GAWAIN, a novel structural measure for geographic atrophy that weights macular regions by their functional importance. This index correlates significantly better with visual acuity than traditional a
A multicenter cohort study of 1.8 million clinic encounters reveals that while clinicians view intraocular pressure as a continuous risk factor, the historical 22 mm Hg cutoff remains a significant psychological trigger for escalating glauc
